Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Divergent impacts of microplastics and related leachates on sediment carbon and nitrogen transformation by regulating microbial communities and functions.

Environmental pollution (Barking, Essex : 1987)·2026
Same author

Overexpression of PagAPX8 promotes poplar growth and enhances tolerance to drought and salt stress.

Plant cell reports·2026
Same author

Postmenopausal Osteoporosis, Endothelial Dysfunction, and Cardiovascular Risk.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases·2026
Same author

Relationship Between Central Sensitization and Genetic Polymorphisms-A Case-Control Study in Fibromyalgia.

European journal of pain (London, England)·2026
Same author

Bioavailable human metabolites of a keratin-derived hydrolysate promote primary human dermal fibroblast activities and protect against oxidative stress-related damages.

Frontiers in nutrition·2026
Same author

Increasing plant protein sources in the diet modulates gut microbiota and tryptophan metabolism in men at cardiometabolic risk.

Gut microbes·2026
Same journal

Humanized mouse models for drug metabolism and drug transport: a systematic review.

Drug metabolism reviews·2026
Same journal

Drug transporters in drug disposition - highlights from the year 2025.

Drug metabolism reviews·2026
Same journal

Herbal supplements and anti-tuberculosis therapy: unlocking hidden interactions for better multidrug-resistant tuberculosis management.

Drug metabolism reviews·2026
Same journal

Identification and characterization of a novel aldehyde metabolite of WIN18,446 and associated WIN18,446-ALDH1A2 protein adducts using mass spectrometry.

Drug metabolism reviews·2026
Same journal

Pharmacomicrobiomics in precision pharmacotherapy: bidirectional microbial-drug interactions as a key determinant of therapeutic response.

Drug metabolism reviews·2026
Same journal

Population pharmacokinetics of levofloxacin: a systematic review.

Drug metabolism reviews·2026
See all related articles

Related Experiment Videos

Paracetamol metabolism and related genetic differences.

Lizi Zhao1, Gisèle Pickering

  • 1Institute of Clinical Pharmacology, Sun Yat-Sen University, Guangzhou, China.

Drug Metabolism Reviews
|November 27, 2010
PubMed
Summary
This summary is machine-generated.

Paracetamol (acetaminophen) metabolism varies by individual genetics, influencing both its effectiveness and potential toxicity. Understanding these pharmacogenetic differences is key to optimizing its therapeutic use.

Related Experiment Videos

Area of Science:

  • Pharmacology
  • Toxicology
  • Genetics

Background:

  • Paracetamol (acetaminophen) is a widely used analgesic and antipyretic.
  • Its metabolism involves multiple pathways, but toxic metabolite accumulation can cause organ damage, especially in overdose.
  • Individual and ethnic variations in metabolism suggest differing susceptibility to toxicity and efficacy.

Purpose of the Study:

  • To review the scientific literature linking paracetamol metabolism and enzyme genotypes.
  • To explore the implications for toxic side effects and therapeutic efficacy.

Main Methods:

  • Literature review of studies on paracetamol metabolism.
  • Analysis of pharmacogenetic data related to enzyme genotypes.
  • Correlation of genetic profiles with paracetamol toxicity and efficacy.

Main Results:

  • Significant intersubject and ethnic variations exist in paracetamol metabolic activation.
  • Specific enzyme genotypes are associated with altered paracetamol metabolism rates.
  • These genetic differences correlate with varying susceptibility to paracetamol-induced toxicity and differences in pain relief.

Conclusions:

  • Pharmacogenetic profiles play a crucial role in determining paracetamol's safety and effectiveness.
  • Understanding these genetic links can guide personalized medicine approaches for paracetamol therapy.
  • Further research into genotype-specific responses is warranted to optimize paracetamol use.